Cleara Biotech
Biotechnology company creating therapeutics targeting cellular senescence by designing novel senolytic compounds that selectively eliminate senescent cells to treat age-related diseases.
Website
https://www.cleara.comLocation
Utrecht, Netherlands
Founded
2017
Investors
1
Categories
therapeutics, biotech, longevity-research, senolytics, aging
Notes
Cleara Biotech is a biotechnology company pioneering the development of senolytic therapies that selectively eliminate senescent cells. Senescent cells accumulate with age and contribute to various age-related diseases and tissue dysfunction. By clearing these cells, Cleara aims to treat conditions associated with aging and improve healthspan.
The company was founded based on research from the University Medical Center Utrecht and is developing novel small molecule senolytic compounds with improved selectivity and safety profiles.
Team
- Peter de Keizer, Ph.D. - Co-founder & Chief Scientific Officer
- LinkedIn: linkedin.com/in/peterdekeizer
- Marco Demaria, Ph.D. - Co-founder & Scientific Advisor
Additional Research Findings
- Backed by Apollo Health Ventures
- Cellular senescence targeting approach
- Senolytic compounds to eliminate senescent cells
- University Medical Center Utrecht spinout
- Focus on age-related diseases
- Novel compound design for improved selectivity
- Headquarters in Utrecht, Netherlands
- Part of longevity/aging research sector
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Apollo Health Ventures | Dusseldorf, Germany / Boston, USA | biotech-focused | seedseries-a+1 | 15 |